AA Amyloidosis: A Contemporary View.
Safak Mirioglu1,2, Omer Uludag3, Ozge Hurdogan4
1Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
Current Rheumatology Reports
|April 3, 2024
Summary
AA amyloidosis, a complication of chronic inflammation, is declining due to better disease treatment. Current management focuses on reducing serum amyloid A protein, with new biologic agents improving outcomes, though amyloid deposit clearance remains a challenge.
Area of Science:
- Rheumatology
- Nephrology
- Cardiology
Background:
- AA amyloidosis is a severe complication of chronic inflammatory conditions.
- It can lead to organ damage and life-threatening outcomes.
- Recent advancements have impacted its management and prognosis.
Purpose of the Study:
- To review the epidemiology of AA amyloidosis.
- To discuss the causes, pathogenesis, and clinical manifestations.
- To outline current and emerging diagnostic and therapeutic strategies.
Main Methods:
- Literature review of AA amyloidosis.
- Analysis of epidemiological trends.
- Evaluation of diagnostic modalities including histopathology and MRI.
- Assessment of therapeutic interventions.
Main Results:
- Incidence of AA amyloidosis has decreased due to improved treatment of underlying inflammatory diseases.
- Histopathology is the gold standard for diagnosis; MRI aids in detecting cardiac involvement.
- Current treatments focus on reducing serum amyloid A protein, with biologic agents significantly improving management.
- Kidney transplantation is effective, with rare recurrence post-transplant due to new therapies.
Conclusions:
- Management of AA amyloidosis has evolved with novel anti-inflammatory therapies.
- Controlling inflammation is key, but agents for amyloid deposit clearance are still needed.
- Further research into direct amyloid-clearing therapies is warranted.
Related Concept Videos
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184